Platelet [3H]imipramine binding in patients with panic disorder.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• The serotonin system, particularly the serotonin transporter (SERT), is implicated in mood and anxiety disorders.
• Imipramine binding to platelets serves as a surrogate marker for SERT density and function.

Purpose of the Study:

• To investigate [3H]imipramine binding to platelets in drug-free patients with panic disorder compared to healthy controls.
• To explore if comorbid conditions like major depression or agoraphobia influence these binding parameters.

Main Methods:

• Quantification of [3H]imipramine binding to platelet membranes.
• Measurement of binding parameters: Bmax (maximum binding capacity) and Kd (dissociation constant).
• Comparison between 17 drug-free panic disorder patients and 14 healthy controls, including subgroups with and without histories of depression or severe agoraphobia.

Main Results:

• No statistically significant differences in Bmax or Kd values were observed between panic disorder patients and healthy controls.
• Panic disorder patients with a history of major melancholic depression or severe agoraphobia exhibited similar binding parameters to those without such histories.

Conclusions:

• Panic disorder, in the absence of medication, does not appear to be associated with alterations in platelet serotonin transporter availability.
• Comorbid major depression or severe agoraphobia did not significantly affect platelet [3H]imipramine binding in panic disorder patients.